Assessing the association of the HNF1A G319S variant with C-reactive protein in Aboriginal Canadians: a population-based epidemiological study

Table 1 Characteristics of participants according to the HNF1AG319S carrier status

Characteristic	G/G319	S/G + S/S319	p
n (%)	554 (78.6)	151 (21.4)
Age (years)*	30.0 ± 15.9	30.6 ± 15.4	0.70
Sex, male†	220 (39.7)	76 (50.3)	0.02
BMI (kg/m²)*	26.6 ± 5.90	27.0 ± 5.22	0.52
Waist circumference (cm)*	97.6 ± 14.7	99.1 ± 13.2	0.24
Hypertension, yes†‡	119 (21.5)	30 (19.9)	0.67
HDL cholesterol (mmol/l)*	1.25 ± 0.28	1.23 ± 0.27	0.46
LDL cholesterol (mmol/l)*	2.59 ± 0.74	2.56 ± 0.79	0.75
Triglyceride (mmol/l) §	1.25 (0.88-1.71)	1.27 (0.97-1.87)	0.06
Fasting glucose (mmol/l) §	5.4 (5.1-5.9)	5.6 (5.0-7.6)	< 0.0001
2-hour postload glucose (mmol/l) §	5.7 (4.4-7.2)	6.0 (4.8-9.8)	0.002
HOMA-insulin resistance§	3.61 (2.38-6.27)	3.96 (2.16-6.87)	0.44
HOMA-beta§	144.4 (98.3-204.5)	110.3 (67.8-180.5)	0.0004
C-reactive protein (mg/l) §	2.17 (0.63-5.73)	1.85 (0.57-5.05)	0.29
Serum amyloid A (mg/l) §	7.71 (4.73-12.98)	7.18 (5.03-11.39)	0.48

Abbreviation: BMI, body mass index; HDL high-density lipoprotein; LDL low-density lipoprotein; HOMA, homoeostasis model assessment. N of subjects for each characteristic varying slightly due to occasional missing values. *Mean ± standard deviation and Welch's t test performed. †n (%) and Chi-Square test performed. ‡Hypertension is defined as a systolic blood pressure ≥130 mmHg or diastolic blood pressure of ≥85 mmHg or receiving antihypertensive medication therapy. §Medians (25^th-75^th percentile) and Welch's t test performed on log transformation.

ISSN: 1475-2840